Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Todd Palmby"'
Autor:
Xiajing Gong, Meng Hu, Jinzhong Liu, Geoffrey Kim, James Xu, Amy McKee, Todd Palmby, R. Angelo de Claro, Liang Zhao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Small molecule kinase inhibitors (SMKIs) are being approved at a fast pace under expedited programs for anticancer treatment. Here, the authors employ a machine-learning model to examine the relationships between kinase targets and adverse events in
Externí odkaz:
https://doaj.org/article/0acfd12fa2c4416da16ad933f8db2dd9
Autor:
Calvin Chen Sheng, MD, Laleh Amiri-Kordestani, MD, Todd Palmby, PhD, Thomas Force, MD, Charles C. Hong, MD, PhD, Joseph C. Wu, MD, PhD, Kevin Croce, MD, PhD, Geoffrey Kim, MD, Javid Moslehi, MD
Publikováno v:
JACC: Basic to Translational Science, Vol 1, Iss 5, Pp 386-398 (2016)
Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional
Externí odkaz:
https://doaj.org/article/6158e6de3f1f4ac5ad684e83913463ba
Autor:
Yang-Min Ning, Nitin Mehrotra, Shenghui Tang, Debasis Ghosh, Lijun Zhang, Amna Ibrahim, Robeena Aziz, Amy Tilley, Richard Pazdur, Robert Justice, Elimika Pfuma, Paul G. Kluetz, Todd Palmby, Rajeshwari Sridhara, V. Ellen Maher, Jeanne Fourie Zirkelbach
Publikováno v:
Clinical Cancer Research. 19:6650-6656
On December 10, 2012, the U.S. Food and Drug Administration granted full approval for a modified indication for abiraterone acetate (Zytiga tablets; Janssen Biotech, Inc.) in combination with prednisone for the treatment of patients with metastatic c
Autor:
Hong Zhao, Dubravka Kufrin, Patricia Keegan, Xiaoping Jiang, Jian Wang, Kun He, Richard Pazdur, Sarah Pope Miksinski, Todd Palmby, Ke Liu, Zedong Dong, Anne M Russell, Michael Axelson
Publikováno v:
Clinical Cancer Research. 19:2289-2293
The data and regulatory considerations leading to the U.S. Food and Drug Administration (FDA) January 30, 2012 approval of Erivedge (vismodegib) capsules for the treatment of patients with recurrent, locally advanced, or metastatic basal cell carcino
Autor:
Qi Liu, Hui Zhang, Pengfei Song, V. Ellen Maher, Martin T. Haber, Eldon Leutzinger, Shenghui Tang, Robert Justice, Elleni Alebachew, William F. Pierce, Paul G. Kluetz, Amna Ibrahim, Todd Palmby, Richard Pazdur, Rajeshwari Sridhara, Ali Al-Hakim, Wei Chen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(1)
On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomat
Autor:
Debasis Ghosh, Amna Ibrahim, Yangmin M. Ning, Richard Pazdur, Rajeshwari Sridhara, Todd Palmby, Shenghui Tang, John Leighton, William F. Pierce, Christy L. Cottrell, Stella Karuri, Qi Liu, V. Ellen Maher, Robert Justice, Nitin Mehrotra, Haw-Jyh Chiu, Dhananjay Marathe, Jeanne Fourie Zirkelbach
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(22)
This article summarizes the regulatory evaluation that led to the full approval of enzalutamide (XTANDI, Medivation Inc.) by the U.S. Food and Drug Administration (FDA) on August 31, 2012, for the treatment of patients with metastatic castration-resi